Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Endocyte Reports DSMB Recommendations Following Interim Futility Analysis

RELATED NEWS
Trade ECYT now with 

Endocyte, Inc. (ECYT: Quote) unveiled the outcomes of the planned independent Data Safety Monitoring Board or DSMB review of the interim futility analysis for the Phase 2b TARGET study with investigational candidate vintafolide. The DSMB urged the continuation of the vintafolide combination therapy and docetaxel monotherapy arms of the trial.

In addition, the DSMB recommended investigators and patients be advised that vintafolide monotherapy is not likely to be declared superior to docetaxel in progression-free survival or PFS at the end of the study, and patients currently on vintafolide monotherapy may continue treatment based on guidance from their investigator. The TARGET trial's top-line results are expected in early 2014.

TARGET is being conducted in non-small cell lung cancer patients with all lesions expressing the folate receptor, as determined by the investigational companion imaging agent etarfolatide. This randomized trial is fully enrolled and comprised two investigational arms, vintafolide monotherapy and vintafolide in combination with docetaxel, each of which is compared to a standard of care control arm, docetaxel monotherapy.

The primary endpoint of the trial is PFS, powered to show a 50 percent improvement in PFS compared to the control arm, while secondary endpoints include the comparison of overall response rate, overall survival and safety.

Register
To receive FREE breaking news email alerts for Endocyte, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Beverages giant Coca-Cola Co. reported Tuesday a profit for the third quarter that decreased 14 percent from last year, despite higher worldwide volumes, reflecting a revenue drop. Adjusted earnings per share matched analysts' expectations, even as quarterly revenues missed their estimates. Following the announcement, the company's shares are trading more than five percent lower in early deals. Apple Inc. said Monday that its fourth quarter profit rose 13% from last year, driven by strong sales of its iPhones and Mac computers. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly sales. At the same time, the company gave an upbeat revenue forecast for the current quarter, which includes the all important holiday season. Programmable chipmaker Xilinx Inc. (XLNX) said Thursday after the markets closed that its second quarter profit rose 21% from last year, helped by higher revenue and better cost control. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue....
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.